Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
generic version
brand name products |
| gptkbp:chemicalFormula |
C15H13BrN2O3S
|
| gptkbp:clinicalTrials |
gptkb:American_Academy_of_Ophthalmology
gptkb:European_Society_of_Cataract_and_Refractive_Surgeons Phase III trials cataract surgery corneal surgery postoperative inflammation |
| gptkbp:contraindication |
allergic reactions
visual disturbances active ocular infection corneal toxicity corneal epithelium defects systemic absorption hypersensitivity_to_bromfenac |
| gptkbp:drugInterdiction |
anticoagulants
other NSAIDs antiplatelet agents methotrexate |
| gptkbp:formulation |
0.09% solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
bromfenac sodium
|
| gptkbp:isATypeOf |
118256-07-2
|
| gptkbp:issuedBy |
ophthalmic solution
|
| gptkbp:lastProduced |
2005
|
| gptkbp:manufacturer |
gptkb:Bausch_+_Lomb
gptkb:Sun_Pharmaceutical_Industries |
| gptkbp:marketedAs |
gptkb:Prolensa
Bromday |
| gptkbp:packaging |
single-use vials
|
| gptkbp:patentExpiration |
2025
|
| gptkbp:patentStatus |
patented
|
| gptkbp:researchAreas |
pain management
anti-inflammatory therapies ocular pharmacology |
| gptkbp:route |
topical
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
headache
stinging eye irritation burning sensation dry eye |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
inhibition of cyclooxygenase enzymes
|
| gptkbp:usedFor |
treatment of inflammation
treatment of pain |